Skip to main content
2/13/2020

Celiac Disease Patients on a Gluten-Free Diet Still Ingest Gluten

Persistent gluten exposure is known to lead to lifelong health issues in people with celiac disease, including anemia, malnutrition, and lymphoma. More and more evidence is showing what many have long suspected: maintaining a truly gluten-free diet may not be possible. Despite the need to protect celiac disease patients against gluten exposure, very little is…

Continue Reading
12/18/2019

Latiglutenase for Celiac Disease Shows Symptom, Quality of Life Improvement

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…

Continue Reading
10/24/2019

Cour Pharmaceuticals Announces Deal with Takeda for Celiac Treatment

Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a small phase 2a study at the annual United European Gastroenterology organization meeting showing that its treatment, CNP-101, cut levels of inflammation-promoting cytokines. The technology was…

Continue Reading